The article focuses on trial data presented by Timothy L. Jackson, a consultant advisory board member of medical company Alcon which found that microvascular lesions induced by external beam X-ray therapy using the IRay stereotactic radiotherapy system for age-related macular degeneration regressed and did not affect visual outcome.